Vertex (VRTX) PT Raised to $220 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Vertex (VRTX) PT Raised to $234 at BMO Capital
February 6, 2019 7:53 AM ESTBMO Capital analyst Do Kim raised the price target on Vertex (NASDAQ: VRTX) to $234.00 (from $192.00) while maintaining a Outperform rating.
Kim commented, "Our target price rises to $234 from $192, as we increase long-term CF revenue projections, following another solid 4Q18 beat on revenues and... More
Maxim Group Downgrades Vertex (VRTX) to Hold
February 6, 2019 7:45 AM ESTMaxim Group analyst Jason McCarthy downgraded Vertex (NASDAQ: VRTX) from Buy to Hold.
The analyst highlighted:
Vertex reported 4Q18 with cystic fibrosis (CF) revenue of $868M, representing sequential growth of 11% and beating consensus of $816M; the results include Kalydeco revenue of $259M vs. $250.5M... MoreVertex (VRTX) PT Lowered to $213 at RBC Capital
February 6, 2019 7:14 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Vertex (NASDAQ: VRTX) to $213.00 (from $215.00) while maintaining a Outperform rating.
... MoreVertex (VRTX) PT Raised to $200 at UBS
February 6, 2019 6:32 AM ESTUBS raised its price target on Vertex (NASDAQ: VRTX) to $200.00 (from $188.00) while maintaining a Neutral rating.
... MoreVertex (VRTX) PT Raised to $216 at JMP Securities
February 6, 2019 4:13 AM ESTJMP Securities raised its price target on Vertex (NASDAQ: VRTX) to $216.00 (from $211.00) while maintaining a Market Outperform rating.
... MoreVertex (VRTX) PT Raised to $218 at Piper Jaffray
February 6, 2019 1:57 AM ESTPiper Jaffray analyst Edward Tenthoff raised the price target on Vertex (NASDAQ: VRTX) to $218.00 (from $217.00) while maintaining a Overweight rating.
... MoreVertex Pharma (VRTX) Tops Q4 EPS by 24c, Revenues Beat; Offers FY19 Revenue Guidance
February 5, 2019 4:03 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $1.30, $0.24 better than the analyst estimate of $1.06. Revenue for the quarter came in at $868 million versus the consensus estimate of $819.12 million.
"Our achievements in 2018 were marked by a significant increase in the number of CF... More
